Autologous haematopoietic stem cell transplantation, in which a patient’s own stem cells are harvested and reinfused after high-dose chemotherapy, is a mainstay of treatment for multiple myeloma, relapsed lymphoma, and certain other haematological malignancies. The procedure works because the chemotherapy ablates the bone marrow and the reinfused cells rebuild it, but the interval between ablation and recovery leaves patients profoundly neutropenic, with absolute neutrophil counts low enough that even ordinary bacterial flora can become life-threatening. During this window, typically one to two weeks post-infusion, patients are nursed in protective isolation, monitored for fever, and managed with broad supportive care. Clinical guidelines define the danger signs clearly, yet the patients living through the window experience it from the inside, and the study set out to understand how they interpret what is happening to them.

The researchers employed a qualitative descriptive design, purposively sampling adults aged eighteen years or older who had undergone autologous transplantation and were currently neutropenic as inpatients in the transplantation unit. The sampling strategy deliberately sought variation across age, diagnosis, and treatment experience so that the findings would not reflect a narrow slice of the transplant population. Data collection consisted of semi-structured interviews, audio-recorded with consent and transcribed verbatim, conducted with twenty-two participants between post-transplant day plus five and day plus eighteen, precisely the period when neutrophil counts bottom out and begin to recover. The transcripts were then analysed using reflexive thematic analysis, an approach in which the researchers explicitly acknowledge and interrogate their own role in shaping the themes that emerge from the data rather than treating themes as if they were simply discovered.

The first major finding concerns how patients conceptualised their symptoms. Rather than reporting discrete problems such as nausea, fatigue, mucositis, or fever as separate items on a checklist, participants described them as interlocking constellations, clusters that rose and fell together and that could only be understood in relation to one another. A bout of diarrhoea paired with a new wave of fatigue carried a different meaning than either symptom alone, and the combination of oral pain with difficulty swallowing was appraised differently from oral pain in isolation. This cluster-based perception aligns with a growing body of symptom science showing that patients experience toxicity burdens holistically, but the study adds a temporal dimension that is often missing from cross-sectional symptom assessments.

That temporal dimension proved to be the hinge of the entire study. Participants did not merely catalogue what they felt; they tracked trajectories, comparing today’s symptoms with yesterday’s and using the direction of change as their primary signal. Worsening intensity, the appearance of new symptom combinations, or symptoms that simply felt different from the previous day prompted a re-appraisal of the situation from expected treatment toxicity to possible deterioration. In contrast, symptoms that followed a familiar course and matched what patients had been told to expect were often interpreted as the ordinary price of the transplant and tolerated without alarm. Fever-related patterns stood apart from this calculus: fever, or the constellation of sensations surrounding it, usually triggered immediate escalation and prompt reporting to staff, reflecting the consistent messaging patients receive about infection risk during neutropenia.

The second major finding concerns the behavioural consequences of these appraisals. Help-seeking during the neutropenic window was not uniform. The researchers identified a spectrum ranging from prompt reporting, in which patients escalated concerns to nursing staff as soon as they noticed a troubling trajectory, to watchful waiting, in which patients monitored symptoms over time before deciding whether to speak up. Some participants practised self-management first, attempting to control a symptom on their own and only reporting if their measures failed, while others withheld information altogether, choosing not to mention certain symptoms unless directly asked. These strategies were not random; they reflected deliberate calculations made under conditions of considerable uncertainty.

Three forces shaped those calculations. The first was uncertainty itself: patients often could not tell whether a symptom belonged to the expected toxicity profile or signalled something dangerous, and that ambiguity made them hesitant to act. The second was perceived legitimacy, the sense that a concern was serious enough to warrant staff attention; patients who judged their symptoms as minor or as things they should be able to endure felt reluctant to raise them. The third was a distinctly relational barrier, a reluctance to bother staff during protective isolation, where nursing contact is already frequent and patients are acutely aware of the workload their care demands. Together, these forces explain why a patient with a genuinely concerning trajectory might wait hours or a full day before mentioning it, a delay that matters enormously when the underlying risk is overwhelming sepsis in a person with essentially no neutrophil reserve.

The clinical implications follow directly from the mechanism the study describes. If patients appraise urgency by tracking symptom clusters and trajectories, then assessment tools that capture symptoms only as static lists will miss the signal patients are actually monitoring. The authors argue for cluster-informed assessment, in which nursing evaluations explicitly ask about combinations of symptoms and how they are changing from day to day, mirroring the cognitive framework patients already use. They also propose escalation coaching, structured conversations in which patients are taught which trajectories warrant immediate reporting, which symptoms can be self-managed with a defined threshold for escalation, and crucially, that reporting a concern is never a burden on staff. Such coaching could convert the watchful waiting and withholding behaviours documented in the study into earlier, safer escalation.

The study’s qualitative design means its findings describe the experiences of twenty-two patients in a single Chinese transplantation unit rather than establishing prevalence across transplant populations, and the authors are careful about the scope of their claims. Nevertheless, the mechanistic insight, that urgency appraisal is built from symptom constellations and their trajectories, is likely to generalise, because it reflects how patients anywhere must reason about their bodies when they cannot rely on laboratory values they cannot see. The work also fills a gap in the supportive care literature, which has extensively quantified symptom burden after transplantation but far less often asked patients how they decide what those symptoms mean.

For oncology nursing, the study arrives at a moment when transplantation volumes are rising globally and supportive care is increasingly delivered through protocols that assume patients will report problems promptly. The Wuxi findings suggest that assumption is fragile, and that the fix is not simply to tell patients to report everything, which ignores the legitimacy calculus and the reluctance to bother staff that the interviews revealed. Instead, the researchers point toward a partnership model in which nurses teach patients the trajectory language of danger, validate the reporting of ambiguous symptoms, and design assessment rounds that ask about clusters and change rather than isolated complaints. In a setting where a single day of delayed recognition can separate a manageable infection from a catastrophic one, teaching patients to read their own symptom constellations may prove to be one of the most cost-effective safety interventions in transplant care.

Subject of Research: Patient symptom appraisal and help-seeking behaviour during neutropenia after autologous haematopoietic stem cell transplantation

Article Title: Symptom clusters and help-seeking behaviours during neutropenia after autologous haematopoietic stem cell transplantation: A qualitative study to inform oncology nursing support

Article References: Jiang, L., Hua, J., Teng, F., Xu, T., Cao, H., & Zhou, J. (2026). Symptom clusters and help-seeking behaviours during neutropenia after autologous haematopoietic stem cell transplantation: A qualitative study to inform oncology nursing support. PLOS One, 21(10), e0361023. https://doi.org/10.1371/journal.pone.0361023

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0361023

Keywords: neutropenia, autologous stem cell transplantation, symptom clusters, help-seeking behaviour, oncology nursing, qualitative research, protective isolation, fever, patient safety, supportive care, thematic analysis, haematological malignancy

The research team, led by Henan Wang and Xindi Liu with corresponding authors Liang Wang and Jia Cong, followed 96 consecutive patients treated between November 2022 and March 2025. All had relapsed or refractory B-cell malignancies, the population in which CAR-T products have shown their greatest success. The median age was 56.5 years, with an interquartile range of 46 to 66.5, reflecting the typical demographic of lymphoma patients referred for cellular therapy. Rather than relying on the older Common Terminology Criteria for Adverse Events alone, the investigators graded blood toxicity using the recently formalized immune effector cell-associated hematotoxicity framework, known as ICAHT, which distinguishes neutropenia, or N-ICAHT, from thrombocytopenia, or T-ICAHT, and tracks each on its own timeline.

That distinction matters clinically. Neutropenia strips patients of their main defense against bacterial and fungal infections, while thrombocytopenia raises the risk of spontaneous bleeding, including intracranial hemorrhage in the most severe cases. The two complications have different kinetics, different risk factors, and different management strategies, yet many earlier studies lumped them together under a single hematologic toxicity label. By separating them, the Beijing team could ask whether the predictors of a crashing neutrophil count differ from the predictors of a crashing platelet count, and the answer turned out to be yes, at least in degree.

The efficacy backdrop of the cohort was consistent with published experience. The overall response rate reached 78.3 percent at one month after infusion and settled to 65.5 percent at three months. Classical acute toxicities were common but rarely severe: cytokine release syndrome occurred in 74.0 percent of patients, yet only 2.1 percent experienced grade 3 or higher episodes, and immune effector cell-associated neurotoxicity syndrome appeared in 10.4 percent of patients, of which 5.2 percent were grade 3 or higher. These figures confirm that in experienced centers the inflammatory toxicities that dominated early CAR-T literature are now largely manageable, leaving hematologic recovery as the dominant safety concern.

The neutrophil data tell a stark story. Grade 3 to 4 neutropenia peaked at day 4 after infusion, when 71.9 percent of patients had severely depleted counts, and although most recovered, 34.7 percent still had severe neutropenia at day 28. Persistent suppression a month after infusion is the point at which infectious risk compounds, since patients remain on prophylactic antivirals and often prophylactic antibiotics, and any breakthrough infection can escalate rapidly. To predict who would fare worst, the team stratified patients using the CAR-HEMATOTOX score, a pre-infusion composite that incorporates baseline blood counts, inflammatory markers such as ferritin and C-reactive protein, and disease burden. The score was calculable in 86 patients, and 31 of them, or 36.0 percent, fell into the high-risk category of 2 or above.

The stratification worked. Severe early N-ICAHT, defined as grade 3 to 4 neutropenia in the early window after infusion, occurred in 16.1 percent of high-risk patients compared with 3.6 percent of low-risk patients, a statistically significant difference with a p value of 0.013. In multivariable logistic regression, where candidate predictors were first filtered through LASSO regression to avoid overfitting, a CAR-HEMATOTOX score of 2 or higher was the only significant predictor of severe early neutropenia, with an adjusted odds ratio of 4.04 and a 95 percent confidence interval of 1.01 to 22.17. For late neutropenia, a different factor emerged: patients who had received bridging therapy, meaning anti-cancer treatment given between lymphodepletion planning and CAR-T infusion, had an adjusted odds ratio of 4.25, with a confidence interval of 1.64 to 10.98, for developing late-phase neutropenia.

Thrombocytopenia told an even sharper story. High-risk patients by CAR-HEMATOTOX developed severe early T-ICAHT at a rate of 74.2 percent versus 25.5 percent in low-risk patients, and late T-ICAHT at 80.6 percent versus 47.3 percent, both differences highly significant with p values below 0.001. The CAR-HEMATOTOX score was the strongest adjusted predictor of both early and late thrombocytopenia, with adjusted odds ratios of 8.22 and 4.20 respectively. The authors suggest this stronger association for platelets may reflect the score’s inclusion of baseline platelet count and inflammatory burden, both of which directly bear on platelet production and consumption. Perhaps the most provocative observation was that 9 of the 10 patients who developed neurotoxicity, 90 percent, also developed thrombocytopenia. The team frames this as hypothesis-generating, noting it may point to shared endothelial injury pathways linking brain vascular leakage and platelet decline, while cautioning that residual confounding cannot be excluded in an observational design.

The study also addressed a long-running practical debate: whether the supportive care used to rescue blood counts might itself fan the inflammatory toxicities of CAR-T. Growth factor support with granulocyte colony-stimulating factor, G-CSF, was given to 78.1 percent of patients, and thrombopoietin receptor agonists, TPO-RA, to 48.9 percent. Neither intervention was associated with an increased rate of grade 3 or higher cytokine release syndrome or neurotoxicity. This is reassuring for clinicians who worry that stimulating recovering myeloid cells could amplify the cytokine storm, and it supports the increasingly common practice of early, aggressive count support in the weeks after infusion. The authors are careful to note that within the limits of the observational design, this finding cannot establish causality in either direction, but it removes a major practical objection to using these drugs.

What the study cannot do, by its own design, is settle questions of causation or generalize beyond a single center. As a retrospective cohort at one Chinese hospital, it captures real-world practice, including the bridging therapies and supportive care patterns actually used, but it lacks the randomization needed to prove that the CAR-HEMATOTOX score modifies risk rather than merely marking it. The confidence interval around the early neutropenia odds ratio, stretching from barely above 1 to more than 22, reflects the modest sample size of 96 patients. Still, the consistency of the signal across both neutropenia and thrombocytopenia, and its alignment with prior validation work on the score in European and American cohorts, strengthens the case that pre-infusion risk stratification should become routine.

The practical implications are immediate. Patients flagged as high risk before infusion could be considered for closer platelet monitoring, earlier thrombopoietin receptor agonist initiation, lower thresholds for transfusion, and heightened vigilance for neurologic symptoms given the observed overlap with ICANS. The finding that bridging therapy predicts late neutropenia adds weight to the argument for minimizing or carefully selecting pre-infusion treatment in patients who can safely proceed directly to CAR-T. As CAR-T therapy expands beyond academic centers into community oncology, tools like the CAR-HEMATOTOX score offer a way to bring sophisticated risk assessment to settings without specialized cellular therapy infrastructure. The Beijing cohort suggests that the era of treating CAR-T hematotoxicity as an unpredictable hazard is ending, replaced by a framework in which the patients most likely to crash are identifiable before the first engineered cell is infused.

Subject of Research: Hematologic toxicity, including neutropenia and thrombocytopenia, following CAR-T cell therapy for B-cell malignancies

Article Title: Analysis of hematologic toxicity profiles following CAR-T cell therapy: a retrospective cohort study

Article References: Wang, H., Liu, X., Li, F., Liang, Y., Zeng, L., Zhu, J., Wang, L., & Cong, J. (2026). Analysis of hematologic toxicity profiles following CAR-T cell therapy: a retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-16932-0

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16932-0

Keywords: CAR-T cell therapy, ICAHT, neutropenia, thrombocytopenia, CAR-HEMATOTOX, hematologic toxicity, B-cell malignancy, cytokine release syndrome, ICANS, G-CSF, thrombopoietin receptor agonist, retrospective cohort study

The research, led by Kristina Warolén and Martin Jädersten of Karolinska University Hospital together with colleagues at Sahlgrenska University Hospital in Gothenburg, compared two cohorts of intensively treated AML patients diagnosed between January 2020 and October 2023. The Stockholm cohort, comprising 116 patients, had access to the Stockholm Region’s hospital-at-home (HaH) service, an infrastructure of 11 healthcare companies operating 38 units across 8 geographic areas. The Gothenburg cohort, 49 patients, received conventional inpatient care without such support. Because both hospitals sit in major urban centers and care is delivered free of charge through Sweden’s universal healthcare system, the researchers hypothesized that the two populations would be broadly comparable, and indeed the cohorts were well matched for age, comorbidity as measured by the Charlson Comorbidity Index, and disease risk according to the European Leukemia Net 2022 classification.

The Stockholm HaH model is remarkable for its scope. At home, patients can receive advanced supportive care that most health systems would consider strictly inpatient territory: intravenous fluids, parenteral nutrition, intravenous medications, and blood and platelet transfusions, the latter sometimes administered at local HaH hubs. Each unit is staffed by physicians, nurses, and other healthcare professionals capable of telephone support and emergency house calls around the clock. Although HaH staff receive no formal additional training in hematology, they manage a wide range of advanced medical conditions in oncology and beyond. Laboratory results are reviewed simultaneously by HaH teams and by junior physicians on the hematology ward through a shared electronic health record, and a joint management plan for transfusions and neutropenic complications is documented for every patient. The maximum distance from a patient’s home to Karolinska University Hospital in Huddinge is around 150 kilometers, and in the Stockholm archipelago, helicopter service is available for emergencies.

The primary endpoint of the study was a composite of death or requirement of a higher level of care, defined as the need for vasopressors, high-flow oxygen or non-invasive ventilation, or intensive care admission, during the first two treatment cycles. The results were striking in their equivalence. After the first cycle, 12 of 116 Stockholm patients (10 percent) met the primary endpoint, compared with 4 of 49 Gothenburg patients (8 percent), a difference that was statistically indistinguishable. Crucially, ten of the twelve Stockholm events occurred in patients who had never been discharged to HaH at all, and five of those patients died during the first cycle. Only two patients discharged to home care were later readmitted requiring a higher level of care, one needing vasopressors for a single day and one needing high-flow oxygen for a single day. No deaths occurred after discharge to HaH.

The efficiency gains, by contrast, were dramatic. During the first cycle, 94 percent of Stockholm patients were discharged, versus just 2 percent in Gothenburg, where 48 of 49 patients remained hospitalized for the entirety of the neutropenic phase. Median inpatient stay after the first cycle was 16 days in Stockholm versus 28 days in Gothenburg, and after the second cycle 9 versus 18 days. Over the first two cycles, Stockholm patients spent on average three additional weeks at home, roughly a third of the entire treatment period. Readmissions were common, with 50 of 109 discharged patients returning to hospital during the first cycle, but the reasons were revealing: clinical deterioration with fever, other symptoms, adherence to older protocols, patients not yet enrolled in the HaH program, persistent fever without deterioration, and in only two cases, patient preference.

Perhaps the most technically interesting finding concerns febrile neutropenia, the fever that signals possible infection during the neutropenic nadir. Among 150 neutropenic episodes in discharged Stockholm patients across the first two cycles, fever developed in 130 cases, or 86.7 percent. Of these, 38 episodes, 29 percent, were resolved entirely with intravenous antibiotics administered at home, while the majority of admitted patients received their first antibiotic dose at home before transfer, minimizing the time from fever onset to treatment. Early administration of antibiotics in febrile neutropenia is known to reduce morbidity and mortality, and the HaH model’s ability to deliver piperacillin-tazobactam, increasingly as a continuous infusion, often within an hour of fever onset may have favorably influenced outcomes even for patients ultimately admitted. Notably, patients treated entirely at home had significantly fewer positive blood cultures, 11 percent versus 39 percent among admitted patients, likely reflecting less severe illness.

The study also generated data relevant to evolving international guidelines. In 42 cases, Stockholm clinicians discontinued intravenous antibiotics while patients were still neutropenic, a practice that the older ECIL-4 guidelines from 2011 discouraged, recommending an additional 24 to 48 hours of hospitalization. In practice, 76 percent of these patients did not need to restart antibiotics within 72 hours, and although ten did restart, none required a higher level of care or died. The updated ECIL-10 guidelines from 2024 now permit close monitoring of neutropenic patients discontinuing antibiotics in either inpatient or outpatient settings, bringing official recommendations into line with what the Stockholm team had been doing for years.

There were also unexpected signals suggesting that home care may do more than merely relocate treatment. Stockholm patients required 40 percent fewer days of intravenous antibiotics than their Gothenburg counterparts across the first two cycles, a difference the authors attribute partly to more liberal use of G-CSF, which can shorten neutropenia by up to five days, but possibly also to faster recovery driven by better nutrition, greater physical activity, and a lower risk of acquiring multidrug-resistant bacteria outside the hospital environment. Intriguingly, while three-month and twelve-month survival were comparable between cohorts, there was a trend toward better long-term survival in Stockholm beyond the first year, with a hazard ratio of 0.62 that did not reach statistical significance but raises the possibility that home-based care supports immune function and tolerance of subsequent therapies, including stem cell transplantation.

The authors are careful about limitations. The retrospective design, modest sample sizes, and reduced statistical power to detect rare but severe adverse events all temper the conclusions, and differences in local practice between the two centers, particularly G-CSF use, complicate direct comparison. Factors such as having a relative at home, distance from hospital, compliance, and language skills likely influenced who could be managed at home but were not systematically evaluated, and there was no structured assessment of patient experience, though routine questionnaires suggested near-universal gratitude for the program, with patients valuing home-cooked meals, emotional support, and time with family. Still, out of nearly 200 episodes of outpatient care of neutropenic AML patients, only 2 percent of readmissions required a higher level of care, no worse than expected for this heavily treated population.

The implications extend well beyond Sweden. As hospital-at-home services expand internationally, driven in part by lessons from the COVID-19 pandemic, which originally pushed the Stockholm program to keep febrile patients home to reduce SARS-CoV-2 exposure and relieve bed shortages, this study offers a practical blueprint for extending home care to one of the most vulnerable populations in oncology. It required no additional on-call staffing or dedicated resources, leveraging existing HaH infrastructure alongside AML-specific protocols. Karolinska has already moved further, offering selected patients consolidation chemotherapy at home via electronic infusion pumps since November 2022, and a prospective study of quality of life, depression, nutrition, and muscle mass is underway. If confirmed in prospective trials, the message is simple and potentially transformative: for many patients with acute myeloid leukemia, the safest place to endure the hardest weeks of treatment may be home.

Subject of Research: Outpatient management of intensively treated acute myeloid leukemia through a hospital-at-home program

Article Title: Hospital at home enables safe and efficient outpatient management of intensively treated acute myeloid leukemia

Article References: Warolén, K., Blennow, O., Ravn Landtblom, A., Nilsson, C., Kullänger Schalling, L., Andersson, C., Lind, C., Hållander, S., Westerberg, S., Stjernfeldt, A.-S., Sporre, E., Leskinen, H., Söderholm, L., Wennström, L., Broliden, P. A., Deneberg, S., Espman, E., von Bahr, L., & Jädersten, M. (2026). Hospital at home enables safe and efficient outpatient management of intensively treated acute myeloid leukemia. Supportive Care in Cancer, 34(10), Article 954. https://doi.org/10.1007/s00520-026-11171-2

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11171-2

Keywords: acute myeloid leukemia, hospital at home, febrile neutropenia, intensive chemotherapy, outpatient care, Karolinska University Hospital, supportive care, intravenous antibiotics, neutropenia, home care, hematology, patient safety

The research team, led by investigators from Helsinki University Hospital, Turku University Hospital, Tampere University Hospital, and the data analytics firm Medaffcon, leveraged a uniquely Finnish advantage: near-complete longitudinal health records. By linking the Finnish Kidney Transplant Registry with regional hospital data lakes, the national inpatient and outpatient register (HILMO), pharmacy purchase records from the Social Insurance Institute, and mortality data from Statistics Finland, the researchers assembled a dataset covering approximately half of the Finnish population. All transplantations occurred between 2013 and 2022, and patients were followed for clinical outcomes during the first 18 months and for healthcare resource utilization up to four years after surgery.

The cohort was stratified by cytomegalovirus serostatus, a critical distinction in transplant medicine. Roughly 73 percent of recipients were CMV-seropositive before transplantation (the R+ group), about 21 percent received a kidney from a seropositive donor while being seronegative themselves (the high-risk D+/R− group), and just over 6 percent were seronegative with seronegative donors (D−/R−). This distribution reflects Finland’s CMV seroprevalence of approximately 70 percent, meaning roughly one in five Finnish transplant recipients falls into the highest-risk category for primary CMV infection after surgery.

The headline finding is stark: post-transplant leukopenia or neutropenia, abbreviated PTLN in the study, occurred in 34.5 percent of all recipients within the first year. But the risk was far from evenly distributed. Among D+/R− recipients, 51.5 percent developed PTLN by 12 months, compared with 31.7 percent of R+ recipients and only 10 percent of D−/R− recipients, a difference that remained highly significant after statistical adjustment. In a multivariable logistic regression model, D+/R− serostatus carried 2.42-fold higher odds of PTLN within 18 months, while D−/R− status was actually protective relative to the R+ reference group.

Beyond serostatus, several other risk factors emerged. Female sex was independently associated with PTLN, a finding the authors attribute in part to sex differences in drug pharmacokinetics that may lead to higher plasma drug exposures in women receiving standard doses. Polycystic kidney disease as the primary diagnosis also increased risk, consistent with prior reports that patients with autosomal dominant polycystic kidney disease frequently have leukopenia even before transplantation, possibly related to splenic sequestration or intrinsic immune dysregulation. Delayed graft function, meaning the transplanted kidney did not immediately work, was another independent risk factor. Perhaps most strikingly, induction therapy with anti-thymocyte globulin (ATG) was associated with a seven-fold increase in PTLN risk, a finding the authors note was unsurprising given ATG’s well-known myelosuppressive effects but clinically important given its increasing use in solid organ transplantation.

The relationship between PTLN and CMV infection proved more nuanced than a simple cause-and-effect story. CMV DNAemia, detectable viral DNA in the blood, occurred at broadly similar frequencies in R+ and D+/R− recipients, roughly half of each group. But the timing differed dramatically. In R+ recipients, the median time to first CMV DNAemia was 66 days, with most episodes occurring within the first six months after transplantation. In D+/R− recipients, the median time was 239 days, with most episodes occurring after the six-month mark, coinciding with the end of their standard six-month valganciclovir prophylaxis. This temporal pattern reflects the different prophylactic strategies: 95 percent of D+/R− patients started valganciclovir prophylaxis at transplantation, compared with only 28 percent of R+ patients, who were instead monitored for CMV DNAemia and treated if it appeared.

Using a multistate model that tracked the sequence of events over time, the researchers uncovered a striking asymmetry. In D+/R− recipients, PTLN tended to precede CMV DNAemia, whereas in R+ recipients, CMV DNAemia was more often detected first. By six months post-transplant, 34.5 percent of D+/R− patients had developed PTLN, only 6 percent had CMV DNAemia, and 7.5 percent had experienced both. Among R+ patients, the pattern was nearly reversed: 14.4 percent had PTLN, 31.3 percent had CMV DNAemia, and 11.9 percent had both. The authors caution that these observational findings do not establish causality, and that in R+ patients it was impossible to reliably distinguish CMV-driven cytopenia from valganciclovir-induced myelosuppression because the registry data lacked complete information on drug dosing and indications. Nevertheless, the temporal patterns are clinically plausible given the different prophylactic regimens each group receives.

The economic dimension of the study may prove to be its most consequential contribution. Patients who developed PTLN had substantially higher healthcare resource utilization across virtually every metric measured. Hospital readmission rates at 12 months were 75.3 percent among R+ patients with PTLN versus 64.6 percent among those without, and 78.9 percent versus 72.9 percent in the D+/R− group. ICU admission rates were also elevated, particularly among R+ patients with PTLN, at 13.8 percent versus 6 percent. The cost differences were even more pronounced: during the first year after transplantation, excluding the initial 30 days, inpatient costs averaged 14,028 euros per patient among those with PTLN compared with 5,716 euros among those without, while outpatient costs were 11,695 euros versus 9,045 euros respectively. These differences persisted into the second year of follow-up.

In a multivariable gamma regression model adjusting for demographics, comorbidities, and transplant characteristics, both D+/R− serostatus and PTLN remained independently associated with higher total healthcare costs over four years. The authors emphasize that these cost estimates should be interpreted conservatively, since PTLN may function as a marker of overall clinical complexity rather than a direct cause of increased spending. Many PTLN episodes are managed in outpatient settings through intensified laboratory monitoring and medication adjustments that do not generate inpatient costs, and the exclusion of the first 30 days after transplantation means early PTLN-related events were not captured in the primary cost model.

Notably, the study did not find statistically significant associations between PTLN and graft loss or mortality, though the authors attribute this partly to the limited number of events and note that prior studies have yielded conflicting results on this question. The five-year patient survival rate for the entire cohort was 87.7 percent, and five-year graft survival was 84.7 percent, with no significant differences by CMV serostatus or PTLN status. Advanced recipient age and diabetes as the primary kidney disease were associated with higher mortality and graft loss risk, while female sex and polycystic kidney disease were associated with better graft survival.

The proportion of patients experiencing PTLN also increased over the study period, from 3.6 percent of those transplanted in 2014–2015 to 8.6 percent of those transplanted in 2020–2022. The authors suggest this trend may reflect changes in clinical practice during the decade, including increasing use of ATG induction, greater reliance on tacrolimus-based immunosuppression, and a moderate expansion of valganciclovir prophylaxis, partly driven by more ABO-incompatible transplants and ATG induction protocols. As transplant populations grow older and frailer, the cumulative immunosuppressive burden from multiple concomitant therapies may further elevate PTLN risk, reinforcing the importance of strategies aimed at mitigating both its clinical and economic consequences.

Subject of Research: Post-transplant leukopenia, neutropenia, and cytomegalovirus infection in kidney transplant recipients

Article Title: The frequency and timing of leukopenia and CMV infections in kidney transplant recipients in Finland – a retrospective observational study

Article References: Helanterä, I., Ortiz, F., Havula, E., Tuominen, S., Hakamäki, M., Hellman, T., Mäkelä, S., & Korhonen, R. (2026). The frequency and timing of leukopenia and CMV infections in kidney transplant recipients in Finland – a retrospective observational study. Transplant International, 39, Article 16893. https://doi.org/10.3389/ti.2026.16893

Image Credits: AI Generated

DOI: 10.3389/ti.2026.16893

Keywords: kidney transplantation, leukopenia, neutropenia, cytomegalovirus, valganciclovir, CMV DNAemia, healthcare resource utilization, transplant immunosuppression, Finland, registry study, donor-recipient serostatus, myelosuppression

The clinical picture in this case unfolded across more than a decade, and the sequence of events illustrates why Felty syndrome remains one of the most diagnostically challenging entities in rheumatology and haematology. The patient’s rheumatoid factor was negative at 2 IU/mL, a detail worth emphasising because Felty syndrome has traditionally been associated with seropositive rheumatoid arthritis. Although anti-cyclic citrullinated peptide antibody testing was not documented, the seronegative presentation may have contributed to the initial diagnostic uncertainty, since clinicians encountering neutropenia and splenomegaly in a seronegative patient with inflammatory joint disease may consider a broader differential diagnosis, including lymphoproliferative disorders, before settling on Felty syndrome. The autoimmune haemolytic anaemia that marked her presentation six years before death added further complexity, as this cytopenia is not part of the classical triad and can point toward overlapping autoimmune and clonal lymphoproliferative processes.

The immunophenotypic findings in this case deserve careful consideration in light of what is known about gamma-delta T-cell biology. Gamma-delta T cells normally constitute a small fraction of the circulating T-cell pool, typically around one to five percent in peripheral blood, and they play important roles in epithelial surveillance and innate-like immune responses. Expansion of a gamma-delta population to approximately eleven percent of analysed cells in the initial splenic specimen, and to roughly twenty percent at splenectomy, represents a substantial deviation from normal proportions. The retrospective detection of this population in archival material is particularly instructive, because it demonstrates that flow cytometric data collected for other clinical purposes can yield critical diagnostic information when re-examined with a specific question in mind. Many laboratories archive flow cytometry data files, and systematic re-review of such datasets in patients with unexplained cytopenias and splenomegaly could potentially identify clonal T-cell populations earlier in the disease course.

The cytoplasmic granules observed in the atypical circulating lymphoid cells during the terminal phase reflect the cytotoxic nature of the neoplasm. Cytotoxic T cells contain specialised granules rich in proteins such as granzymes and perforin, and the expression of TIA-1, a granule-associated protein detected in both the splenic lymphocytes and the autopsy tumour cells, is a hallmark of this lineage. Cytotoxic T-cell large granular lymphocytic leukaemia, whether of alpha-beta or gamma-delta type, shares this phenotype, and the granular morphology visible on blood films is often one of the earliest morphological clues that a lymphocytosis is not merely reactive. In this patient, the emergence of conspicuous granules in atypical circulating cells coincided with the rapid rise in lactate dehydrogenase, a biochemical marker of high cellular turnover that ultimately exceeded 8000 U/L, roughly thirty-five times the upper limit of the reference range. Such extreme elevations of lactate dehydrogenase in lymphoid malignancies generally indicate high tumour burden, rapid cell turnover, or tissue destruction, and in this case served as a biochemical harbinger of the aggressive terminal phase.

The immunophenotype of the autopsy tumour cells, being positive for CD3, CD7, and TIA-1 but negative for CD5, CD4, and CD8, warrants comment. Loss of CD5, a pan-T-cell marker normally expressed on mature T cells, is a well-recognised aberrancy in T-cell large granular lymphocytic leukaemia and related clonal cytotoxic disorders. The double-negative CD4 and CD8 status, combined with the gamma-delta lineage suggested by the flow cytometric findings, is consistent with the double-negative gamma-delta cytotoxic phenotype that has been described in a subset of T-cell large granular lymphocytic leukaemia cases, particularly those associated with autoimmune conditions. The preservation of CD7, which is often retained in T-cell large granular lymphocytic leukaemia but frequently lost in more aggressive T-cell lymphomas, illustrates the difficulty of definitive subclassification in this terminal phase, a point the authors themselves acknowledged.

The molecular findings merit detailed discussion because they connect this case to a growing body of knowledge about somatic mutations in chronic clonal cytotoxic T-cell disorders. Activating mutations in STAT3, the gene encoding signal transducer and activator of transcription 3, are the most frequently identified somatic alterations in T-cell large granular lymphocytic leukaemia, detected in a substantial proportion of patients. The p.G618R substitution identified here lies within the SH2 domain, the region responsible for binding phosphorylated tyrosine residues on receptor tails. Mutations in this domain impair the negative regulatory mechanisms that normally keep STAT3 signalling transient, resulting in constitutive activation of downstream transcriptional programmes that promote survival and proliferation of the clonal cytotoxic cells. This sustained signalling helps explain the characteristic persistence and gradual expansion of the clonal population over years, and it also provides a mechanistic link to the autoimmune features that frequently accompany these disorders, since chronically activated cytotoxic T cells can contribute to neutropenia through antibody-independent mechanisms such as Fas-mediated apoptosis of neutrophil precursors.

The concurrent TET2 frameshift mutation adds another layer of biological interest. TET2 encodes a methylcytosine dioxygenase involved in DNA demethylation, and loss-of-function mutations in this gene are among the most common alterations in clonal haematopoiesis of indeterminate potential, an age-related phenomenon in which hematopoietic stem cell clones expand without overt malignancy. In the context of T-cell large granular lymphocytic leukaemia, TET2 mutations are frequent and may contribute to the survival advantage of the clonal cells, although their presence alone does not establish malignant transformation. The coexistence of a STAT3 mutation providing survival signalling with a TET2 mutation altering epigenetic regulation mirrors patterns seen in myeloid neoplasms, where the combination of a signalling pathway mutation and an epigenetic regulator mutation is a common theme in clonal evolution. The variant allele frequencies of 38.2 percent and 31.9 percent in the autopsy bone marrow indicate that the dominant neoplasm carried both mutations in a large fraction of cells, consistent with a clonal population in which these alterations were early founding events rather than late subclonal acquisitions.

The temporal relationship established by the allele-specific polymerase chain reaction analysis is arguably the most informative element of the molecular work. By demonstrating that STAT3 p.G618R was undetectable in the first three bone marrow examinations but detectable in the fourth and fifth, coinciding with the emergence of detectable T-cell receptor gamma-chain rearrangement, the investigators established a sequence in which the molecular clone became apparent only in the later phase of a disease that had been clinically stable for years. This stepwise pattern supports a model in which a small pre-existing clone, below the detection threshold of conventional testing, gradually expanded until it became demonstrable, and subsequently acquired additional genomic abnormalities, including the complex karyotype, that propelled the terminal aggressive transformation. The complex karyotype itself, with structural abnormalities of the X chromosome, duplications of chromosome 1 material, additions on chromosomes 2 and 5, and trisomy 9, reflects the accumulating genomic instability that often accompanies malignant progression in lymphoid neoplasms.

Several practical implications follow from this case for clinicians caring for patients with Felty syndrome or suspected T-cell large granular lymphocytic leukaemia. First, the absence of overt abnormalities on early bone marrow examinations does not exclude an incipient clonal process, and the retrospective identification of an expanded gamma-delta population in the initial splenic specimen suggests that careful multiparameter flow cytometry, with attention to gamma-delta T-cell proportions and aberrant marker expression, should be considered in patients with Felty syndrome who have unexplained or progressive cytopenias. Second, T-cell receptor gene rearrangement studies, which were not performed on the early bone marrow specimens in this case, can provide evidence of clonality that immunophenotyping alone may not establish, and their inclusion in the initial workup of suspected cases could shorten the diagnostic delay. Third, the detection of STAT3 mutations by sensitive methods such as allele-specific polymerase chain reaction can identify clonal disease before morphological or immunophenotypic evidence becomes apparent, although the presence of such mutations in patients without overt malignancy, as part of the spectrum of clonal cytosis of uncertain significance, means that positive results must be interpreted in clinical context.

The authors appropriately acknowledged limitations in their analysis, including the reliance on peripheral blood mononuclear cells as the comparator specimen because non-haematopoietic tissue was unavailable. This limitation is not trivial, since clonal haematopoiesis of indeterminate potential becomes increasingly common with advancing age, and low-level mutant clones in the blood could theoretically confound the interpretation of mutation testing in elderly patients. However, the complete absence of the STAT3 and TET2 mutations in the peripheral blood comparator, combined with their high variant allele frequencies in the splenectomy and autopsy specimens, strongly favours the interpretation that these mutations characterised the disease-associated clone rather than an incidental age-related process. The use of Sanger sequencing, which has a detection threshold of roughly ten to twenty percent variant allele frequency, means that smaller subclones carrying the same mutations would not have been detected, leaving open the possibility that the clone existed at low levels for longer than the molecular testing could demonstrate.

Beyond the individual case, this report contributes to a broader conceptual shift in how the boundary between autoimmune disease and clonal lymphoproliferation is understood. Felty syndrome and T-cell large granular lymphocytic leukaemia share not only clinical features, including neutropenia, splenomegaly, and association with rheumatoid arthritis, but also molecular features, with recurrent STAT3 mutations documented in both conditions. Some investigators have proposed that these entities represent points on a continuum rather than distinct diseases, with the proportion of clonal cells and the presence of additional genomic abnormalities determining where along that continuum a given patient falls. The present case, with its fourteen-year history of rheumatoid arthritis, its four-year clinical course diagnosed as Felty syndrome, and its terminal transformation into an aggressive clonal T-cell neoplasm, provides a longitudinal illustration of this continuum, showing how a chronic, indolent clonal process can remain clinically silent for years before acquiring the additional alterations that drive aggressive behaviour.

The rarity of aggressive transformation in this setting is itself noteworthy. Most patients with T-cell large granular lymphocytic leukaemia follow an indolent course, and the condition is generally managed conservatively, with treatment directed at the cytopenias rather than at eradication of the clone. Transformation to aggressive lymphoma is uncommon, and when it occurs, it is often associated with additional genetic events such as TP53 alterations, which were notably absent in this case despite the aggressive terminal course. This observation suggests that other genomic mechanisms, potentially involving the complex chromosomal abnormalities identified by cytogenetics, can drive aggressive progression independently of TP53, and it underscores the need for comprehensive genomic characterisation in such cases to identify the full complement of driver alterations. As larger cohorts of patients with Felty syndrome and associated clonal cytotoxic T-cell disorders are studied with modern sequencing technologies, the molecular determinants of transformation are likely to become clearer, potentially enabling risk stratification and earlier intervention in patients whose clonal populations show features associated with aggressive potential.

Subject of Research: Evolution of Felty syndrome-associated clonal cytotoxic T-cell disease into terminal aggressive T-cell lymphoma with shared STAT3 and TET2 mutations

Article Title: Felty Syndrome–Associated Clonal Cytotoxic T‐Cell Disease With Terminal Aggressive Progression: Shared STAT3 and TET2 Mutations Across a Prolonged Disease Course

Article References: Saito, K., Yokohama, A., Kwan Ee, O., Sorimachi, M., Imamura, K., Kobayashi, N., Miyazawa, Y., Ogawa, Y., Saito, T., Shirakura, T., Nobusawa, S., & Handa, H. (2026). Felty Syndrome–Associated Clonal Cytotoxic T‐Cell Disease With Terminal Aggressive Progression: Shared STAT3 and TET2 Mutations Across a Prolonged Disease Course. eJHaem, 7(5), Article e70406. https://doi.org/10.1002/jha2.70406

Image Credits: AI Generated

DOI: 10.1002/jha2.70406

Keywords: Felty syndrome, rheumatoid arthritis, T-cell large granular lymphocytic leukemia, STAT3 mutation, TET2 mutation, clonal hematopoiesis, TCR clonality, aggressive T-cell lymphoma, whole-exome sequencing, autopsy pathology, clonal evolution, neutropenia

The research team, working under PRISMA 2020 reporting guidelines, searched PubMed, Scopus and Google Scholar for studies published up to March 2026, including only observational studies that reported the prevalence of VRE among patients with blood cancers and related conditions. Study quality was evaluated with the Joanna Briggs Institute checklist, and the pooled estimate was generated using a random-effects meta-analysis of logit-transformed proportions, a statistical approach well suited to prevalence data that range widely across studies. Calculations were performed in OpenMetaAnalyst and Comprehensive Meta-Analysis software, giving the authors two independent platforms to verify their results.

The headline figure of 18.4 percent, with a 95 percent confidence interval of 15.5 to 21.6 percent, conceals an extraordinary degree of variation between individual studies. The heterogeneity statistic I2 came in at 97.56 percent, with a p-value below 0.001, meaning that almost all of the observed variability between studies reflects real differences in settings, populations and methods rather than random statistical noise. In practical terms, the global average is a useful warning sign, but the true risk for any given patient depends heavily on where they are treated and what kind of haematological condition they have.

That geographic variation proved to be one of the most striking findings. South America recorded the highest pooled prevalence at 25.5 percent, followed by Australia at 22.8 percent, while other continents showed lower but still clinically significant levels. Meta-regression formally confirmed what the subgroup analysis suggested: continent was a significant contributor to heterogeneity, with a Cochran’s Q statistic of 11.68 and a p-value of 0.0395. By contrast, the laboratory detection method and the type of clinical sample tested were not significant moderators, suggesting that the differences are driven by genuine epidemiological factors—local antibiotic prescribing patterns, infection control infrastructure and regional strain ecology—rather than by how the bacteria were measured.

The patient-level breakdown is where the analysis becomes most alarming. Among haematopoietic stem cell transplantation recipients, the pooled prevalence of VRE reached 97.1 percent, a figure that approaches universality. Neutropenic patients, whose white blood cell defences have been stripped away by chemotherapy, showed a pooled prevalence of 91.2 percent, and patients with acute myeloid leukemia, the most aggressive of the common leukemias, came in at 68.3 percent. These subgroups represent patients whose immune systems are either deliberately ablated for transplantation or destroyed by disease and its treatment, leaving them almost defenceless against organisms that healthy people carry harmlessly in their gut.

Enterococci are intestinal commensals, organisms that normally live in the human gut without causing disease. The danger arises when the gut barrier is breached by intensive chemotherapy, mucositis from high-dose conditioning regimens, or prolonged neutropenia, allowing bacteria to enter the bloodstream. Vancomycin resistance, mediated primarily by the vanA and vanB gene clusters that alter the bacterial cell-wall target, means that first-line empirical therapy for febrile neutropenia may simply fail. For immunocompromised patients, a VRE bloodstream infection is not a routine resistant bug but a potentially fatal event with limited treatment options, often requiring linezolid or daptomycin, drugs with their own toxicity and resistance problems.

The authors were transparent about the limitations of their evidence base. Publication bias was detected through funnel plot asymmetry, with Egger’s regression test yielding a p-value of 0.0224 and Begg’s test a p-value of 0.0226, both statistically significant. This pattern suggests that smaller studies reporting higher prevalence figures were more likely to be published than those reporting low or null findings, which means the pooled estimate of 18.4 percent may be somewhat inflated relative to the true global figure. Sensitivity analyses were conducted to probe the robustness of the pooled result, and the systematic review was prospectively registered with the Open Science Framework, adding a layer of methodological accountability that is not always present in prevalence syntheses.

Why does this matter now? Antimicrobial resistance is frequently framed as a problem of intensive care units and long-term care facilities in high-income countries, but this analysis shows that the epicentre of risk sits squarely within haematology wards and transplant units worldwide. Patients with leukemia and lymphoma undergo repeated hospital admissions, receive broad-spectrum antibiotics for extended periods, and are exposed to the selective pressure that VRE needs to colonise and outcompete susceptible gut flora. The near-universal prevalence among transplant recipients suggests that in this population, VRE colonisation has become less an exception than the expected baseline in many centres.

The clinical implications follow directly from the numbers. Empirical antibiotic guidelines for febrile neutropenia may need to account for local VRE prevalence, with centres in high-prevalence regions such as South America and Australia potentially requiring earlier coverage of resistant enterococci. Surveillance cultures, gut decolonisation strategies and stringent contact precautions in transplant units are logical responses, though the review stops short of evaluating interventions. What the data do establish is a benchmark: any haematology service can now compare its own VRE rates against a rigorously pooled global estimate and its continental and patient-subgroup reference points.

For researchers, the 97.56 percent heterogeneity is both a caveat and a research agenda. The finding that continent, but not detection method or sample type, explains part of that variation points toward modifiable regional factors—antibiotic stewardship, infection control investment and healthcare-associated transmission networks—as the levers most likely to move prevalence. As the population of patients surviving blood cancers grows and more people undergo stem cell transplantation each year, the reservoir of immunocompromised hosts in whom VRE can flourish will only expand. This review provides the clearest quantitative picture yet of that reservoir, and it suggests that the window for containing vancomycin-resistant enterococci in haematology is narrowing.

Subject of Research: Global prevalence of vancomycin-resistant Enterococcus in patients with haematological malignancies

Article Title: Global prevalence of vancomycin-resistant Enterococcus in patients with haematological malignancies: a systematic review and meta-analysis

Article References: Aljebaly, F. S. M. (2026). Global prevalence of vancomycin-resistant Enterococcus in patients with haematological malignancies: a systematic review and meta-analysis. Frontiers in Public Health, 14, Article 1945305. https://doi.org/10.3389/fpubh.2026.1945305

Image Credits: AI Generated

DOI: 10.3389/fpubh.2026.1945305

Keywords: vancomycin-resistant Enterococcus, haematological malignancies, antimicrobial resistance, meta-analysis, systematic review, stem cell transplantation, neutropenia, acute myeloid leukemia, healthcare-associated infections, infection control, public health, Frontiers in Public Health

The underlying condition, neutropenic septic shock, is among the most feared complications of cancer treatment. Chemotherapy does not distinguish between malignant cells and the rapidly dividing cells of the bone marrow, so it often wipes out neutrophils, the white blood cells that form the body’s first line of defense against bacterial and fungal invasion. When an infection takes hold in a neutropenic child, it can progress with terrifying speed. Bacterial toxins and the resulting inflammatory cascade damage blood vessels, causing them to dilate and leak, while the myocardium itself becomes depressed by circulating inflammatory mediators. Blood pressure falls, organs are starved of oxygen, and despite aggressive fluid resuscitation and escalating doses of vasopressor medications, the circulation may simply refuse to respond. This state, known as refractory septic shock, carries a high mortality risk and historically has been viewed as a relative contraindication to ECMO support.

The hesitation is understandable. VA ECMO involves cannulating large blood vessels, typically the jugular vein and carotid artery in the neck or the femoral vessels in the groin, and diverting blood through an external circuit where a membrane oxygenator removes carbon dioxide and adds oxygen before a pump returns the blood to the arterial system. This provides both cardiac and respiratory support, effectively taking over the work of the failing heart. But the machine requires systemic anticoagulation to prevent clotting in the circuit, and anticoagulation in a patient with no neutrophils, disseminated intravascular coagulation, and fragile bone marrow is a recipe for catastrophic bleeding. Critics have also worried that ECMO cannulation could seed infection in an already septic, immunocompromised patient, and that children with cancer have such poor prognoses that the enormous resource investment is not justified.

The Seoul team challenged those assumptions with a carefully reasoned selection strategy. Their retrospective single-center study included only patients who met three criteria: refractory septic shock that could not be stabilized with conventional therapy, an anticipated potential for hematologic recovery, meaning the bone marrow was expected to rebound and produce neutrophils again, and the absence of uncontrolled malignancy or prior hematopoietic stem cell transplantation. This third criterion is crucial, because it distinguishes between a transient, potentially reversible state of immunosuppression and a permanent or progressive one. Chemotherapy-induced neutropenia, the authors emphasize, is often temporary. If the marrow can be given time, sometimes just a few days, the neutrophil count recovers and the immune system can begin fighting the infection on its own. ECMO, in this framework, is not a cure but a bridge, buying the body time to reach that recovery point.

The four patients in the study had a median age of 13.0 years, and all underwent peripheral VA ECMO cannulation. What makes the outcomes striking is the timing of hematologic recovery relative to extracorporeal support. In every case, neutrophil recovery occurred before, during, or shortly after the ECMO run, confirming that the team’s selection criteria had correctly identified children whose bone marrow was poised to rebound. All four patients were successfully weaned from ECMO after a median support duration of just 5.0 days, a relatively short run that suggests the mechanical support was used precisely as intended, as a temporary bridge across the most dangerous phase of shock rather than a prolonged dependence. Every patient survived to hospital discharge, and none showed neurologic injury, a critical measure in pediatric critical care where hypoxic brain damage is a common and devastating consequence of prolonged circulatory collapse.

The study is equally candid about its complications, and one case in particular carries an important technical lesson. In a single patient, the team attempted to place a distal perfusion catheter, a small cannula inserted downstream of the arterial cannulation site to restore blood flow to the limb on the cannulated side. Peripheral femoral arterial cannulation can compromise perfusion of the leg because the ECMO circuit diverts blood away from the distal vessels. In this patient, the catheter could not be placed at all, because severe vasoconstriction and small-caliber vessels made the procedure technically infeasible. The child subsequently developed severe limb ischemia, the death of tissue deprived of blood flow, and ultimately required amputation. This complication underscores that in septic children, whose vasculature is clamped down by both shock physiology and vasopressor drugs, limb protection strategies must be planned before cannulation, and alternative cannulation sites or techniques should be considered when distal perfusion is not achievable.

Encouragingly, no life-threatening hemorrhagic or neurologic complications were observed in any of the four patients, despite the traditional fears about anticoagulation in this population. The authors attribute this in part to a restrictive anticoagulation strategy, meaning the team deliberately kept heparin dosing and anticoagulation targets conservative, accepting a higher risk of circuit clotting in exchange for a lower risk of bleeding in a patient population already prone to coagulopathy. Modern heparin-bonded circuits and careful monitoring make such strategies increasingly feasible. The combination of peripheral cannulation, restrictive anticoagulation, and strict patient selection appears to have been central to the favorable outcomes, and the authors highlight timely multidisciplinary decision-making as a fourth pillar, bringing pediatric intensivists, hematologists, oncologists, surgeons, and ECMO specialists to the bedside together rather than serially.

The significance of this work lies less in its size than in its proof of concept. Four patients is a small sample, and the retrospective, single-center design means the results cannot be generalized without caution. Centers with different resources, patient mixes, or ECMO volumes might see different outcomes. Nevertheless, the study provides concrete evidence against the reflexive exclusion of neutropenic children from ECMO candidacy. Previous literature has been sparse and largely discouraging, with many centers citing bleeding and infection concerns as reasons to withhold extracorporeal support from immunocompromised patients. By demonstrating that a structured selection process, one that hinges on the reversibility of the neutropenia and the absence of uncontrolled disease, can identify children who not only tolerate ECMO but survive it with good neurologic outcomes, the Seoul group has shifted the conversation from whether to support these patients to how to select and manage them.

The broader implications reach into how pediatric intensive care units approach the immunocompromised child in extremis. As survival from childhood cancer continues to improve, the population of children receiving intensive chemotherapy grows, and with it the number who will encounter life-threatening infections during periods of profound neutropenia. The concept of ECMO as a bridge to hematologic recovery reframes the technology in a way that aligns with modern transplant and oncology practice, where temporary mechanical support is routinely used to bridge patients to recovery or definitive therapy. The key insight is that the neutropenia itself is not the barrier; the barrier is whether the marrow will recover. When clinicians can answer that question with reasonable confidence, the calculus of offering ECMO changes fundamentally.

For now, the authors’ conclusions remain measured. VA ECMO, they write, may be a viable rescue therapy for carefully selected pediatric patients with chemotherapy-induced neutropenic septic shock in whom hematologic recovery is anticipated. The emphasis on careful selection is not hedging but the heart of the finding. The four survivors in this study were chosen precisely because their disease was controlled, their marrow was expected to rebound, and their shock was refractory but not yet irreversible. Larger multicenter studies will be needed to define the optimal timing of cannulation, the best anticoagulation protocols, and the long-term outcomes of these children. But for families and clinicians confronting the bleakest moments of pediatric septic shock, the message from Seoul is one of cautious hope: with the right patient, the right timing, and a disciplined multidisciplinary team, the heart-lung machine can carry a child through the storm until their own immune system returns to fight.

Subject of Research: VA ECMO as rescue therapy for chemotherapy-induced neutropenic septic shock in children

Article Title: Venoarterial extracorporeal membrane oxygenation for chemotherapy-induced neutropenic septic shock in children: a single-center experience

Article References: Lee, W. Y., Lee, K. H., Kang, H. M., Yoo, J. W., Chung, N.-G., & Lee, I. K. (2026). Venoarterial extracorporeal membrane oxygenation for chemotherapy-induced neutropenic septic shock in children: a single-center experience. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07709-2

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07709-2

Keywords: VA ECMO, septic shock, neutropenia, chemotherapy, pediatrics, critical care, extracorporeal membrane oxygenation, refractory shock, limb ischemia, anticoagulation, bone marrow recovery, pediatric intensive care

For years, clinical guidelines have drawn a bright line at twenty percent. If a chemotherapy regimen is expected to cause febrile neutropenia in at least one in five patients, guidelines from the American Society of Clinical Oncology, the European Organisation for Research and Treatment of Cancer, and the National Comprehensive Cancer Network recommend giving granulocyte colony-stimulating factor, or G-CSF, prophylactically from the first cycle. This injected growth factor stimulates the bone marrow to keep producing neutrophils through the nadir of each chemo cycle, and randomized evidence shows it reduces both febrile neutropenia and chemotherapy-associated mortality. The trouble is that the twenty percent figure for R-CHOP has rested largely on trial data, and a new systematic review argues that those data may systematically understate what actually happens in ordinary clinics.

The review, published in Supportive Care in Cancer by Jamiel Reyes and Alexander Reyes, took an unusually careful approach to this question. The authors searched MEDLINE, CENTRAL, ClinicalTrials.gov, Europe PMC, Epistemonikos, Lens.org, Google Scholar, and citation trails from inception through 8 September 2026, looking for studies that reported febrile neutropenia incidence in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP or R-CHOP-like immunochemotherapy. The protocol was prospectively registered in PROSPERO, and the team assessed risk of bias with the ROBINS-I tool for observational studies and RoB 2 for randomized trials, then graded the certainty of the evidence using the GRADE framework.

Fifteen studies covering 5,440 patients and 885 febrile neutropenia events made the final analysis. But the authors did something that many meta-analyses of this kind skip: they stratified everything by study design, pooling observational cohorts separately from clinical trials. The rationale is technical but important. Trials and routine-practice cohorts measure the same complication under materially different conditions, and blending them can produce a single number that describes neither setting well. In trials, patients tend to be fitter, monitoring is more intensive, supportive care protocols are more standardized, and prophylactic G-CSF use is often higher and more consistent than in the community.

The observational stratum told a strikingly consistent story. Across ten cohorts enrolling 4,020 patients, the pooled incidence of febrile neutropenia was 19.0 percent, with a 95 percent confidence interval of 17.1 to 21.1 percent. Heterogeneity was low, with an I-squared statistic of just 34 percent, meaning the studies agreed with one another far more than is typical in meta-analyses of this kind. The prediction interval, which estimates where a future study would likely fall, ran from 15.3 to 23.3 percent, and the estimate proved stable across every sensitivity analysis and leave-one-out test the authors performed, including a prespecified analysis restricted to the nine cohorts using core R-CHOP. In other words, no single study was driving the result.

The trial stratum looked very different. Five clinical trials enrolling 1,420 patients yielded a pooled febrile neutropenia incidence of 11.7 percent, but with a confidence interval stretching from 5.7 to 22.7 percent and an I-squared of 79.4 percent, indicating severe heterogeneity. Individual trial estimates ranged from 2.4 to 20.0 percent, a nearly tenfold spread that makes the pooled figure difficult to interpret. The formal comparison between the two designs did not reach conventional statistical significance, with a p-value of 0.051, but the authors note that the difference depended substantially on a single trial. When the large 2013 trial by Cunningham and colleagues comparing 14-day and 21-day R-CHOP schedules was omitted, the trial-stratum estimate shifted to 15.5 percent and the gap between designs essentially disappeared.

What does this mean for the twenty percent threshold? The observational estimate of 19.0 percent sits squarely at, not below, the conventional trigger for primary G-CSF prophylaxis, and its prediction interval crosses well above it. The authors’ conclusion is blunt: in routine practice, approximately one in five adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy develops febrile neutropenia, and trial-derived estimates should not be assumed to represent this real-world burden. For clinicians who have been reassured by trial figures suggesting the risk is closer to one in ten, the message is that the community setting may be considerably riskier than the pages of a phase 3 protocol suggest.

The mechanistic reasons for the discrepancy are not hard to reconstruct. Trial populations are enriched for patients who meet strict eligibility criteria, often excluding older adults with multiple comorbidities, patients with poor performance status, and those with the very risk factors, such as advanced age, elevated lactate dehydrogenase, bulky disease, and low baseline blood counts, that observational studies have repeatedly linked to febrile neutropenia. Trials also tend to enforce prophylactic growth factor use more rigorously and to monitor neutrophil counts on tight schedules, catching problems before they become fevers. Real-world cohorts, by contrast, capture the full spectrum of patients, including elderly and frail individuals who make up a large share of diffuse large B-cell lymphoma diagnoses, and they reflect the uneven adoption of prophylaxis in everyday oncology.

The stakes extend beyond the acute emergency itself. Febrile neutropenia is one of the leading causes of chemotherapy dose reductions and treatment delays, and for a curable disease like diffuse large B-cell lymphoma, compromised dose intensity can translate directly into worse survival. Earlier research, including the INC-EU prospective observational study and analyses of R-CHOP delivery by Pettengell and colleagues, documented how neutropenic complications disrupt treatment schedules and drive hospitalizations. Prophylactic G-CSF, particularly the long-acting pegfilgrastim given once per cycle, has been shown to preserve relative dose intensity, and studies in patients aged 75 and older suggest it reduces mortality in this vulnerable group. If roughly one in five unselected patients experiences a febrile neutropenia event without adequate prophylaxis, the case for applying the guideline threshold generously, rather than treating it as a ceiling, becomes considerably stronger.

The review is not without caveats, and the authors are transparent about them. The between-design difference was not statistically significant at the conventional threshold, and the analysis was reported as an observation rather than a hypothesis test. The registered protocol underwent three amendments, including replacing a comparative outcome with patient-level febrile neutropenia incidence as the primary endpoint and adopting the design stratification during revision, changes the authors documented in the PROSPERO record. All fifteen studies were pooled irrespective of design in a secondary analysis, yielding 17.0 percent with high heterogeneity of 83.3 percent, a figure that illustrates precisely why the stratified approach matters: pooling across designs produces a number with a confidence interval so wide and an I-squared so high that it obscures the two very different realities it averages together. Still, the core observational finding is robust, low-heterogeneity, and consistent with the biological logic of the regimen. As newer first-line options such as polatuzumab vedotin-based therapy enter wider use and add their own myelosuppressive profiles to the mix, the review’s central lesson will only grow in relevance: when deciding who needs prophylactic growth factors, the numbers that count are the ones from the clinic down the street, not just the ones from the trial protocol.

Subject of Research: Febrile neutropenia incidence in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy

Article Title: Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence

Article References: Reyes, J., & Reyes, A. (2026). Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence. Supportive Care in Cancer, 34(10), Article 1065. https://doi.org/10.1007/s00520-026-11301-w

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11301-w

Keywords: diffuse large B-cell lymphoma, febrile neutropenia, R-CHOP, G-CSF, primary prophylaxis, meta-analysis, systematic review, real-world evidence, supportive care, neutropenia, rituximab, clinical trials

The rationale for the biweekly approach is rooted in the realities of real-world oncology practice. In the pivotal trials that established GA as standard therapy, patients were carefully selected, often younger and fitter than the typical person who walks into a community cancer clinic. Once the regimen moved into routine care, clinicians observed that the three-doses-per-cycle schedule produced substantial hematologic toxicity, particularly neutropenia, as well as the peripheral neuropathy that is a signature adverse effect of the taxane class. These toxicities accumulate over successive cycles, and many patients end up receiving less drug than intended, potentially undermining the very efficacy that made the regimen attractive in the first place. The biweekly schedule was conceived as a way to give patients more recovery time between infusions, reducing the nadir burden and allowing fuller doses to be maintained over a longer treatment course.

To evaluate this strategy, the investigators conducted a comprehensive literature search across PubMed, Embase, Web of Science, Scopus, and the Cochrane Library, covering all records from database inception through February 2026 and following PRISMA reporting guidelines. They included both retrospective and prospective studies that compared biweekly GA with the standard weekly schedule in advanced or metastatic pancreatic ductal adenocarcinoma. Two reviewers independently carried out study selection, data extraction, and risk of bias assessment, with methodological quality evaluated using the ROBINS-I tool, which is designed specifically for non-randomized intervention studies. The primary outcomes of interest were overall survival and toxicity, while progression-free survival served as a secondary endpoint. Because the included studies differed substantially in design, populations, and reported parameters, the authors determined that a formal meta-analysis was not statistically appropriate, and they instead summarized their findings descriptively.

That search ultimately identified five retrospective studies meeting the inclusion criteria. In the studies that evaluated a standard-dose biweekly regimen, meaning gemcitabine at 1000 milligrams per square meter of body surface area and nab-paclitaxel at 125 milligrams per square meter, median overall survival ranged from 9.1 to 10 months, and median progression-free survival ranged from 4.8 to 5.4 months. These figures are strikingly consistent with historical benchmarks from the phase III MPACT trial, which established the weekly GA schedule, and with the control arm of the more recent NAPOLI 3 trial, which tested the NALIRIFOX regimen. In other words, cutting one infusion out of each 28-day cycle did not appear to cost patients meaningful survival time in these real-world cohorts, a finding that carries considerable practical weight for clinicians weighing tolerability against efficacy.

Not every dataset pointed in the same direction, however. One large population-based study of elderly patients, encompassing 1,303 individuals, reported a shorter median overall survival of 7.6 months with modified schedules. The authors of the review attribute this shortfall primarily to lower baseline performance status in that geriatric population rather than to the dosing interval itself, an important nuance that underscores how patient selection shapes outcomes in observational research. Elderly patients with advanced pancreatic cancer often present with comorbidities, frailty, and advanced disease burden that independently predict poorer survival, making direct comparisons with younger trial populations hazardous. This caveat is a recurring theme in real-world oncology evidence, and it highlights why the review’s authors call for prospective randomized trials before any definitive change to clinical guidelines.

Where the biweekly schedule truly distinguished itself was in its safety profile. Across the included studies, patients receiving GA on days 1 and 15 experienced lower rates of grade 3 or higher neutropenia, fewer episodes of febrile neutropenia, and less peripheral neuropathy compared with standard three-dose-per-cycle dosing. These are not trivial differences. Severe neutropenia exposes patients to potentially life-threatening infections and often triggers dose delays, while peripheral neuropathy is among the most feared and persistent toxicities of taxane-based therapy, capable of diminishing quality of life long after treatment ends. By extending the interval between infusions, the biweekly schedule appears to allow bone marrow recovery and nerve tissue respite, translating into fewer treatment interruptions and, plausibly, better adherence to the intended therapeutic course.

The technical logic behind this tolerability advantage is worth unpacking. Gemcitabine is a nucleoside analog that incorporates into replicating DNA and triggers masked chain termination, while nab-paclitaxel is an albumin-bound formulation of paclitaxel that stabilizes microtubules and blocks mitosis; the albumin carrier also exploits tumor vasculature to raise intratumoral drug concentrations. Both agents hit rapidly dividing compartments, and the bone marrow is among the most proliferatively active of these. Weekly dosing within a 28-day cycle means the marrow faces repeated insults with only seven days of recovery, and the nadir in neutrophil counts deepens with each successive exposure. A 14-day interval doubles that recovery window, allowing neutrophil counts to rebound more completely before the next challenge. For peripheral nerves, which have limited regenerative capacity, longer intervals may similarly reduce cumulative axonal injury, though the review’s descriptive nature means these mechanistic interpretations remain hypotheses rather than demonstrated mechanisms.

The review’s conclusions are deliberately measured. The authors state that biweekly GA appears to be a feasible and well-tolerated dosing strategy, with survival outcomes overlapping historical weekly GA cohorts in advanced or metastatic pancreatic ductal adenocarcinoma. They emphasize that while prospective randomized trials are needed, the reproducibility of both efficacy and tolerability findings across independent real-world cohorts supports biweekly GA as a viable alternative. That word, reproducibility, is central to the argument. A single retrospective study showing equivalent survival with fewer toxicities could be dismissed as chance or selection bias, but five separate cohorts converging on the same pattern, across different healthcare systems and patient populations, lends the finding a credibility that individual studies cannot achieve on their own.

For patients and clinicians, the practical implications are immediate even if the evidence remains observational. Advanced pancreatic cancer carries a median survival measured in months, and every week spent recovering from preventable toxicity is a week of diminished quality of life and potentially delayed subsequent therapy. If a biweekly schedule can deliver comparable survival with fewer hospitalizations for febrile neutropenia and less disabling neuropathy, it represents a meaningful improvement in the therapeutic ratio, achieved not with a new drug but with a smarter deployment of existing ones. Such schedule optimization is an underappreciated lever in oncology, often cheaper and faster to implement than drug development, though it requires the same rigorous testing standards.

The road ahead runs through prospective, randomized comparison. The review’s authors are explicit that their findings, however encouraging, cannot substitute for controlled evidence, and the heterogeneity that prevented meta-analysis also limits the precision of any single estimate. Still, the study offers a clear hypothesis for trialists to test: that in metastatic pancreatic ductal adenocarcinoma, gemcitabine plus nab-paclitaxel given biweekly at full doses can match the weekly schedule on survival while reducing grade 3 or higher neutropenia, febrile neutropenia, and peripheral neuropathy. If future randomized data confirm what these five real-world cohorts suggest, the standard of care for one of medicine’s most stubborn cancers could be refined not by adding a new agent, but by subtracting a dose, giving patients the same fight with a lighter burden to carry.

Subject of Research: Biweekly versus weekly gemcitabine plus nab-paclitaxel dosing for advanced pancreatic cancer

Article Title: Biweekly gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a systematic review

Article References: Hoyek, C., Eslinger, C., Pirozzi, A., Zhu, M., Borad, M., Wu, C., Ahn, D., Bekaii-Saab, T., & Sonbol, M. B. (2026). Biweekly gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a systematic review. BMC Cancer. https://doi.org/10.1186/s12885-026-17023-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17023-w

Keywords: pancreatic cancer, gemcitabine, nab-paclitaxel, biweekly dosing, dose optimization, systematic review, metastatic pancreatic ductal adenocarcinoma, chemotherapy toxicity, neutropenia, peripheral neuropathy, overall survival, real-world evidence

The guideline, grounded in evidence-based medicine and expert consensus, uses the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework to classify both the quality of evidence and the strength of each recommendation. Evidence quality ranges from high, where the true effect is likely close to the estimate, to very low, where substantial uncertainty remains. Recommendation strength is binary: strong recommendations signal that benefits clearly outweigh harms, while weak recommendations reflect an uncertain balance. This transparent architecture is intended to help oncologists, hematologists, supportive-care teams, and emergency physicians apply the guidance consistently, with particular attention to tumor types, regimens, and patient populations common in Chinese clinical practice.

The epidemiological data assembled by the guideline authors paint a striking picture of risk. Conventional cytotoxic chemotherapy remains the dominant driver of neutropenic events: taxane-based regimens produce Grade III to IV neutropenia in 45.7 percent of patients, anthracycline-based combinations reach 63.2 percent, and platinum agents cause moderate myelosuppression affecting 38.9 percent of those treated. Newer modalities carry their own hazards. Antibody-drug conjugates such as trastuzumab deruxtecan are associated with neutropenia rates of 23.6 to 41.5 percent, while cyclin-dependent kinase 4/6 inhibitors and PARP inhibitors present an intermediate risk profile spanning 8.5 to 42.1 percent. Even immune checkpoint inhibitors, which are far less directly myelotoxic, still trigger Grade III to IV neutropenia in 3.2 to 15.4 percent of patients, primarily through indirect immune-mediated mechanisms.

Radiotherapy, often overlooked in discussions of myelosuppression, receives detailed quantitative treatment in the guideline. Pelvic irradiation carries the highest risk, with an 18.3 percent incidence of absolute neutrophil counts below 1.0 x 10^9 per liter, followed by thoracic irradiation at 9.7 percent and cranial irradiation at 4.1 percent. Dosimetric analyses reveal a linear correlation between the volume of irradiated active bone marrow and the degree of neutrophil decline: once the irradiated volume exceeds 20 percent, the risk of hematologic toxicity rises 2.3-fold. Concurrent chemoradiotherapy, especially platinum-based regimens combined with abdominopelvic radiation, compounds these effects. Notably, proton therapy can reduce active bone marrow exposure by 30 to 50 percent through Bragg peak optimization, offering a physical route to myeloprotection.

At the cellular level, the guideline explains why these treatments hit the bone marrow so hard. Neutrophils arise from hematopoietic stem cells through sequential differentiation over a maturation period of 7 to 14 days, and the marrow reserve holds roughly 2.5 x 10^12 mature neutrophils, some 12 to 20 times the circulating count. Granulocyte colony-stimulating factor (G-CSF) boosts production three- to fivefold via the JAK2/STAT3 pathway, which is precisely why exogenous G-CSF has become the cornerstone of prophylaxis. Different drug classes injure this system in distinct ways: microtubule-targeting agents like paclitaxel disrupt mitosis in hematopoietic stem cells, platinum compounds induce DNA cross-linking that activates p53-dependent apoptosis in myeloid progenitors, and anthracyclines generate reactive oxygen species that damage marrow stromal cells and the cytokine networks supporting granulopoiesis.

The mechanisms of targeted and immunotherapies are equally mechanistically specific. CDK4/6 inhibitors arrest cycling hematopoietic precursors in the G1 phase, PARP inhibitors impose synthetic lethality on proliferating myeloid cells by crippling DNA repair, and tyrosine kinase inhibitors targeting FLT3 or JAK2 directly interfere with granulocyte-macrophage colony-stimulating factor signaling. Immune checkpoint inhibitors suppress myelopoiesis indirectly by inhibiting the JAK/STAT pathway in CD34-positive progenitor cells through interferon-gamma, while the cytokine release syndrome associated with CAR-T therapy promotes neutrophil sequestration via endothelial activation and tissue infiltration. Understanding these divergent pathways, the authors argue, is essential for anticipating which patients will nadir when, since counts typically bottom out 7 to 14 days after chemotherapy and high-risk regimens warrant twice-weekly monitoring.

Diagnostically, the guideline anchors severity to the National Cancer Institute CTCAE version 5.0 criteria: Grade 1 corresponds to an absolute neutrophil count of 1.5 to 2.0 x 10^9 per liter, Grade 2 to 1.0 to 1.5, Grade 3 to 0.5 to 1.0, and Grade 4 to below 0.5. Febrile neutropenia is defined as an ANC below 0.5 x 10^9 per liter, or below 1.0 with an anticipated fall below 0.5 within 48 hours, accompanied by a single oral temperature of at least 38.3 degrees Celsius, or at least 38.0 degrees sustained for more than one hour. Before the first chemotherapy cycle, clinicians are directed to stratify patients into high-risk (above 20 percent febrile neutropenia risk), intermediate-risk (10 to 20 percent), and low-risk (below 10 percent) categories based on regimen intensity and patient factors such as age over 65, prior cytotoxic exposure, marrow involvement by tumor, poor nutritional status, and impaired hepatic or renal function. High-risk patients should receive primary prophylaxis during the first cycle, and all patients should be re-evaluated before subsequent cycles to determine whether secondary prophylaxis or dose adjustment is needed.

On the pharmacological front, the guideline gives a strong, high-quality-evidence endorsement to pegylated recombinant human G-CSF (PEG-rhG-CSF) as the preferred option for patients at high risk of febrile neutropenia. Randomized controlled trials show the long-acting pegylated formulation is at least as effective as short-acting rhG-CSF, with significantly greater dosing convenience and comparable safety, and cost-effectiveness analyses generally favor it within conventional thresholds. Timing matters: prophylactic PEG-rhG-CSF should be administered within 24 to 72 hours after chemotherapy, and healthcare claims data clearly favor next-day use, with same-day administration associated with significantly higher rates of antibiotic use and chemotherapy modification. The guideline also reviews newer agents, including trilaciclib, which significantly reduced the duration of severe neutropenia in Chinese patients with extensive-stage small cell lung cancer, and plinabulin, which matches pegfilgrastim’s efficacy with same-day dosing and a more favorable safety profile. Intriguingly, structured physical exercise is highlighted as a feasible non-pharmacological complement, with moderate-intensity aerobic activity recommended between chemotherapy cycles for high-risk patients.

Managing the side effects of myeloid growth factors receives its own detailed section. Bone pain, the most common adverse reaction, stems from increased intramedullary pressure and histamine-mediated inflammation and is treated first with NSAIDs such as acetaminophen or ibuprofen, escalating to opioids for severe cases. Allergic reactions can emerge minutes to days after administration and require immediate drug discontinuation, antihistamines, glucocorticoids, and emergency intervention for life-threatening symptoms. Rarer but serious complications include splenic rupture, signaled by left upper quadrant pain, progressive anemia, and hypotension, and pulmonary toxicity, which is why routine co-administration of G-CSF with bleomycin-containing regimens such as ABVD in Hodgkin lymphoma is not recommended. A leukemoid reaction, marked by white-cell counts above 30 x 10^9 per liter with immature cells but no malignant features, typically resolves within 3 to 7 days after stopping the drug.

Finally, the guideline addresses the infectious consequences of febrile neutropenia with a risk-stratified antibiotic strategy. Initial evaluation must identify infection sites, from the gastrointestinal tract and lungs to intravascular devices, and collect timely blood cultures from both peripheral and central sources. Two validated scoring systems guide triage: the MASCC index, where scores of 21 or above indicate low risk of infectious complications, and the CISNE model, which incorporates performance status, comorbidities, mucositis, monocyte count, and stress-induced hyperglycemia. Patients with febrile neutropenia need prompt broad-spectrum antibiotics with antipseudomonal coverage, empiric antifungal therapy reserved for persistent fever unresponsive to antibacterials, and careful de-escalation when risk assessment allows. Looking ahead, the authors point to high-frequency temperature monitoring, microbiome evaluation, immunogenic risk assessment, and machine learning as the next frontier for personalizing antibiotic use, alongside structured patient and caregiver education delivered from the start of therapy and reinforced throughout treatment.

Subject of Research: Clinical guideline for the prevention and management of neutropenia induced by anticancer therapy

Article Title: CACA guidelines for managing cancer therapy-induced neutropenia (2026)

Article References: Xiao, L., Wang, F., Yuan, Y., Xia, S., Qin, W., Zhang, X., Deng, Y., Yuan, X., Ba, Y., Zhang, J., & China Anti-Cancer Association Committee of Neoplastic Supportive-Care (CONS) (2026). CACA guidelines for managing cancer therapy-induced neutropenia (2026). Holistic Integrative Oncology, 5(1), Article 30. https://doi.org/10.1007/s44178-026-00234-3

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00234-3

Keywords: neutropenia, febrile neutropenia, chemotherapy, G-CSF, PEG-rhG-CSF, CACA guidelines, supportive care, radiotherapy, immunotherapy, bone marrow toxicity, antibiotic stewardship, oncology